Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruiyirong vs Myfortic in de novo kidney transplant recipients
NCT05872568Phase 4Not yet recruiting
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of mycophenolate sodium in kidney transplant rejection (2 arms). Primary endpoint: Incidence of acute rejection at 12 months. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT05872568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872568.